Pure Global
NCT06328283

The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients

The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of GLutamine Synthetase and BCLAF1 in Diagnosis of Hepatocellular in Cirrhotic Patients
Sohag University·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
measure of Glutamine synthetase and BCLFAF1
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Sohag University
Location
Sohag, Egypt
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Mar 01, 2026
Enrollment
90 participants
Primary outcome

glutamine synthetase

Summary

Hepatocellular carcinoma (HCC) is the most prominent kind of liver cancer, accounting for 85%
 of primary liver malignancies. It is a very aggressive tumor, having a terrible prognosis and
 poor survival rate HCC is ranked as the sixth most common type of cancer and the third
 leading cause of cancer-related mortalities world wide.
 
 HCC incidences arise in complications associated with chronic liver disease like cirrhosis,
 endemic hepatitis B virus (HBV)/hepatitis C virus (HCV) infections, non alcoholic fatty liver
 disease (NAFLD), and alcohol-related liver disease (Torre, 2015).

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06328283
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06328283 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.